Prospective Multicentric Randomized Phase III Study of Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors Comparing Interruption Versus Continuation of Treatment Beyond 1 Year: The French Sarcoma Group

2007391 citationsJournal Article

Authors

Jean‐Yves Blay · Université Claude Bernard Lyon 1

Axel Le Cesne · Université Claude Bernard Lyon 1

Isabelle Ray‐Coquard · Université Claude Bernard Lyon 1

Binh Bui · Université Claude Bernard Lyon 1

Florence Duffaud · Université Claude Bernard Lyon 1

Catherine Delbaldo · Université Claude Bernard Lyon 1

Antoine Adenis

Abstract

Imatinib interruption results in rapid progression in most patients with advanced GIST, and cannot be recommended in routine practice unless patient experience significant toxicity

Topics & Keywords

Gastrointestinal Tumor Research and Treatment Gastric Cancer Management and Outcomes Sarcoma Diagnosis and Treatment

Publication Details

Published in: Journal of Clinical Oncology

Volume 25, Issue 9, pp. 1107-1113

DOI: 10.1200/jco.2006.09.0183

Field-Weighted Citation Impact: 26.51

Command Palette

Prospective Multicentric Randomized Phase III Study of Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors Comparing Interruption Versus Continuation of Treatment Beyond 1 Year: The French Sarcoma Group

Authors

Abstract

Topics & Keywords

Publication Details